AB0438 Efficacy and Safety of Tabalumab, an Anti-B Cell Activating Factor Monoclonal Antibody, in Patients with Rheumatoid Arthritis WHO HAD an Inadequate Response to Tnf-Alpha Inhibitors: Results from A Phase 3 Multicenter, Randomized, Double-Blind Study

FRI0326 Efficacy and Safety of Tabalumab, an Anti-B Cell Activating Factor Monoclonal Antibody, in Patients with Rheumatoid Arthritis Who HAD an Inadequate Response to Methotrexate Therapy: Results from A Phase 3 Multicenter, Randomized, Double-Blind Study

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2014-eular.1535 ◽

2014 ◽

Vol 73 (Suppl 2) ◽

pp. 504.2-504

Author(s):

J.S. Smolen ◽

M.E. Weinblatt ◽

D. van der Heijde ◽

W.F. Rigby ◽

R. van Vollenhoven ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

B Cell ◽

Methotrexate Therapy ◽

Double Blind Study ◽

Inadequate Response ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2014-207090 ◽

2015 ◽

Vol 74 (8) ◽

pp. 1567-1570 ◽

Cited By ~ 20

Author(s):

Josef S Smolen ◽

Michael E Weinblatt ◽

Désirée van der Heijde ◽

William F C Rigby ◽

Ronald van Vollenhoven ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

B Cell ◽

Methotrexate Therapy ◽

Phase Iii ◽

Double Blind Study ◽

Inadequate Response ◽

Efficacy And Safety ◽

Double Blind ◽

Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study

RMD Open ◽

10.1136/rmdopen-2014-000037 ◽

2015 ◽

Vol 1 (1) ◽

pp. e000037 ◽

Cited By ~ 12

Author(s):

Michael Schiff ◽

Bernard Combe ◽

Thomas Dörner ◽

Joel M Kremer ◽

Thomas W Huizinga ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Tnf Inhibitors ◽

Inadequate Response ◽

Efficacy And Safety ◽

Severe Rheumatoid Arthritis ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

SAT0219 Upadacitinib in patients with active rheumatoid arthritis and inadequate response or intolerance to biological dmards: a phase 3 randomized, placebo-controlled, double-blind study of a selective jak1 inhibitor

10.1136/annrheumdis-2018-eular.4180 ◽

2018 ◽

Author(s):

M. C. Genovese ◽

R. Fleischmann ◽

B. Combe ◽

S. Hall ◽

Y. Zhang ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Blind Study ◽

Double Blind Study ◽

Inadequate Response ◽

Phase 3 ◽

Double Blind ◽

Biological Dmards

Efficacy and Safety of Tabalumab, an Anti–B-Cell–Activating Factor Monoclonal Antibody, in a Heterogeneous Rheumatoid Arthritis Population

JCR Journal of Clinical Rheumatology ◽

10.1097/rhu.0000000000000276 ◽

2015 ◽

Vol 21 (5) ◽

pp. 231-238 ◽

Cited By ~ 6

Author(s):

Mark C. Genovese ◽

Gregg J. Silverman ◽

Paul Emery ◽

Ramesh C. Gupta ◽

Anne Gill ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

B Cell ◽

Efficacy And Safety ◽

Rheumatoid Arthritis Population ◽

OP0035 Upadacitinib as monotherapy: a phase 3 randomised controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate

10.1136/annrheumdis-2018-eular.4237 ◽

2018 ◽

Cited By ~ 3

Author(s):

J. Smolen ◽

S. Cohen ◽

P. Emery ◽

W. Rigby ◽

Y. Tanaka ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Blind Study ◽

Double Blind Study ◽

Inadequate Response ◽

Phase 3 ◽

Double Blind ◽

Randomised Controlled

OP0036 A phase 3 randomised, placebo-controlled, double-blind study of upadacitinib (ABT-494), a selective jak-1 inhibitor, in patients with active rheumatoid arthritis with inadequate response to conventional synthetic dmards

10.1136/annrheumdis-2018-eular.3131 ◽

2018 ◽

Author(s):

G. Burmester ◽

J. Kremer ◽

F. van den Bosch ◽

Y. Li ◽

Y. Zhou ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Blind Study ◽

Double Blind Study ◽

Inadequate Response ◽

Phase 3 ◽

Double Blind ◽

Synthetic Dmards

Results of A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of The Efficacy And Safety of Sirukumab, An Anti-IL-6 Cytokine Monoclonal Antibody, In Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment (Sirround-D)

Value in Health ◽

10.1016/j.jval.2016.09.1074 ◽

2016 ◽

Vol 19 (7) ◽

pp. A531 ◽

Cited By ~ 2

Author(s):

T Takeuchi ◽

C Thorne ◽

G Karpouzas ◽

S Sheng ◽

W Xu ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Disease Modifying ◽

Rheumatic Drug

Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in Active Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3523879 ◽

2020 ◽

Author(s):

Yoshiya Tanaka ◽

Tsutomu Takeuchi ◽

Hisashi Yamanaka ◽

Toshihiro Nanki ◽

Hisanori Umehara ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Inadequate Response ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Efficacy and Safety of E6011, an Anti‐Fractalkine Monoclonal Antibody, in Active Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results of a Randomized, Double‐blind, Placebo‐controlled Phase 2 study

Arthritis & Rheumatology ◽

10.1002/art.41555 ◽

2020 ◽

Author(s):

Yoshiya Tanaka ◽

Tsutomu Takeuchi ◽

Hisashi Yamanaka ◽

Toshihiro Nanki ◽

Hisanori Umehara ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Inadequate Response ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study